AstraZeneca (AZN) Acquires Neuroscience Assets from Mazzachusetts-Based Link Medicine
Tweet Send to a Friend
Up)
AstraZeneca (NYSE: AZN) has acquired a portfolio of neuroscience assets from Link Medicine Corporation, a privately held biopharmaceutical company based in Massachusetts, USA. Link Medicine has focused its research and development efforts in the field of autophagy, an intracellular process that clears and recycles misfolded proteins and has been developing potential new treatments for a range of neurodegenerative diseases.
AstraZeneca acquired multiple small molecule assets in clinical and preclinical stage that target the enzyme farnesyltransferase and modulate autophagy. Autophagy is an emerging area of research that can be applied to a range of neurodegenerative diseases, including Parkinson's and Alzheimer's disease. Both of these conditions are characterised by a build-up of incorrectly folded, aggregated and ultimately neurotoxic proteins.
Under the terms of the agreement, AstraZeneca will make specified upfront and milestone payments and will assume all of the programme's research and development activities. The financial terms of the deal have not been disclosed.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
AstraZeneca acquired multiple small molecule assets in clinical and preclinical stage that target the enzyme farnesyltransferase and modulate autophagy. Autophagy is an emerging area of research that can be applied to a range of neurodegenerative diseases, including Parkinson's and Alzheimer's disease. Both of these conditions are characterised by a build-up of incorrectly folded, aggregated and ultimately neurotoxic proteins.
Under the terms of the agreement, AstraZeneca will make specified upfront and milestone payments and will assume all of the programme's research and development activities. The financial terms of the deal have not been disclosed.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Correct: Buying Warner Chilcott plc (WCRX) Seen as Takeover Defense by Actavis (ACT)
- Sanofi (SNY) Reports JAKARTA Met Primary Endpoint in Both Groups
- Oramed Pharma (ORMP) OK'd by FDA for ORMD-0801 IND
Create E-mail Alert Related Categories
Corporate News, FDA, Mergers and Acquisitions
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
